Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more
Hofseth BioCare ASA (HOFBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.367x
Based on the latest financial reports, Hofseth BioCare ASA (HOFBF) has a cash flow conversion efficiency ratio of -0.367x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($27.73 Million) by net assets ($-75.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hofseth BioCare ASA - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Hofseth BioCare ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hofseth BioCare ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hofseth BioCare ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wetteri
HE:WETTERI
|
0.085x |
|
Grande Hospitality Real Estate Investment Trust
BK:GAHREIT
|
0.000x |
|
Kingsmen Resources Ltd
OTCQB:KNGRF
|
0.002x |
|
Groupe Partouche SA
PA:PARP
|
0.108x |
|
FAIR ISAAC
BE:FRI
|
-0.235x |
|
Telefield Inc
KQ:091440
|
-0.077x |
|
Tayih Lun An Co Ltd
TWO:8107
|
0.006x |
|
Baumer S.A
SA:BALM3
|
0.022x |
Annual Cash Flow Conversion Efficiency for Hofseth BioCare ASA (2010–2025)
The table below shows the annual cash flow conversion efficiency of Hofseth BioCare ASA from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-75.53 Million | $-15.61 Million | 0.207x | +229.05% |
| 2024-12-31 | $61.30 Million | $-9.82 Million | -0.160x | -338.63% |
| 2023-12-31 | $41.14 Million | $2.76 Million | 0.067x | +121.99% |
| 2022-12-31 | $148.03 Million | $-45.17 Million | -0.305x | +30.67% |
| 2021-12-31 | $140.38 Million | $-61.78 Million | -0.440x | -88.34% |
| 2020-12-31 | $263.76 Million | $-61.63 Million | -0.234x | +11.42% |
| 2019-12-31 | $117.75 Million | $-31.06 Million | -0.264x | +20.71% |
| 2018-12-31 | $86.04 Million | $-28.62 Million | -0.333x | +51.59% |
| 2017-12-31 | $37.08 Million | $-25.48 Million | -0.687x | +45.24% |
| 2016-12-31 | $53.56 Million | $-67.23 Million | -1.255x | -612.71% |
| 2015-12-31 | $32.55 Million | $7.97 Million | 0.245x | +131.04% |
| 2014-12-31 | $78.95 Million | $-62.26 Million | -0.789x | +41.55% |
| 2013-12-31 | $62.00 Million | $-83.65 Million | -1.349x | -34.11% |
| 2012-12-31 | $47.72 Million | $-48.01 Million | -1.006x | -522.78% |
| 2011-12-31 | $120.53 Million | $-19.47 Million | -0.162x | +1.39% |
| 2010-12-31 | $75.97 Million | $-12.45 Million | -0.164x | -- |